Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Sep;5(3):239-45.
doi: 10.1016/j.jceh.2015.06.004. Epub 2015 Jul 9.

Animal Models Correlating Immune Cells for the Development of NAFLD/NASH

Affiliations
Review

Animal Models Correlating Immune Cells for the Development of NAFLD/NASH

Srikanth Iyer et al. J Clin Exp Hepatol. 2015 Sep.

Abstract

This review mainly elaborates on the animal models available for understanding the pathogenesis of the second hit of non-alcoholic fatty liver disease (NAFLD) involving immune system. This is known to be a step forward from simple steatosis caused during the first hit, which leads to the stage of inflammation followed by more serious liver conditions like non-alcoholic steatohepatitis (NASH) and cirrhosis. Immune-deficient animal models serve as an important tool for understanding the role of a specific cell type or a cytokine in the progression of NAFLD. These animal models can be used in combination with the already available animal models of NAFLD, including dietary models, as well as genetically modified mouse models. Advancements in molecular biological techniques enabled researchers to produce several new animal models for the study of NAFLD, including knockin, generalized knockout, and tissue-specific knockout mice. Development of NASH/NAFLD in various animal models having compromised immune system is discussed in this review.

Keywords: APPs, acute-phase proteins; BAFF, B cell activating factor; Btk, Bruton's tyrosine kinase gene; DAMPs, damage-associated molecular patterns; HCC, hepatocellular carcinoma; IRFs, Interferon regulatory factors; JNK, c-Jun N-terminal kinase; MCD, methionine choline-deficient; NAFLD; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; NLRs, Nod-like receptors; PAMPs, pathogen-associated molecular patterns; immune cells; mouse models.

PubMed Disclaimer

References

    1. Bugianesi E., McCullough A.J., Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology. 2005;42:987–1000. - PubMed
    1. Ludwig J., Viggiano T.R., McGill D.B., Oh B.J. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55:434–438. - PubMed
    1. Judith E., Alexander D., Jan-Peter S. Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Epidemiology. 2011;128:2436–2443. - PubMed
    1. Bellentani S., Scaglioni F., Marino M., Bedogni G. Epidemiology of non-alcoholic fatty liver disease. Dig Dis. 2010;28(1):155–161. - PubMed
    1. Paschos P., Paletas K. Non alcoholic fatty liver disease and metabolic syndrome. Hippokratia. 2009;13(1):9–19. - PMC - PubMed